Seeking Alpha

Dupixent® (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Seeking Alpha

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...
Yahoo UK & Ireland

Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma

Paris and Tarrytown, NY - March 2, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of Dupixent ® (dupilumab) as an add-on ...
MedPage Today

Dupilumab Proves Effective in Chronic Spontaneous Urticaria

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.
Healio

Dupilumab associated with significant reductions in mucus plugging, volume

Please provide your email address to receive an email when new articles are posted on . IL-13, which dupilumab blocks, induces nitric oxide production, which leads to mucus hypersecretion. At week 24, ...
Healio

Chronic spontaneous urticaria symptoms improve with dupilumab through 24 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Approximately half of patients do not respond to H1 ...
Kaleido Scope

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...
Medscape

FDA Expands Dupilumab for EoE to Younger Children

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron/Sanofi) for the treatment of eosinophilic esophagitis (EoE) in children aged 1-11 years and weighing ≥ 15 kg. It ...
Medscape

FDA Calls for More Data on Dupilumab for Chronic Spontaneous Urticaria, Manufacturers Announce

The US Food and Drug Administration (FDA) has issued a complete response letter regarding the application for approval of dupilumab for the treatment of chronic spontaneous urticaria (CSU) in people ...
The American Journal of Managed Care

Dupilumab Considered Safe, Effective for AD in Real-Life Settings

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety. Dupilumab is an effective and safe treatment ...
manilatimes

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
Nasdaq

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

TARRYTOWN, N.Y. and PARIS, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal ...